Criteria for Eligibility to Cisplatin in the Curative Treatment of Head and Neck Cancer: Consensus Opinion from a Panel of Experts

Squamous-cell carcinoma of the head and neck (SCCHN) is an important problem in Brazil, where epidemiological and socioeconomic features often create barriers to the implementation of combined modalities with curative potential. Cisplatin improves the efficacy of radiotherapy in the adjuvant treatment of localized SCCHN and in the definitive therapy of locally advanced disease. However, the addition of high-dose cisplatin to radiotherapy increases treatment toxicity and is not always warranted. A panel of experts convened in Sao Paulo, Brazil, for discussions and recommendations regarding the use of high-dose cisplatin in combination with radiotherapy in SCCHN.

Source: Critical Reviews in Oncology Hematology - August 27, 2018 Category: Cancer & Oncology Authors: Gilberto de Castro, Gustavo V. Alves, Ana F. Castro, Aline L.F. Chaves, Pedro De Marchi, Thiago B. de Oliveira, Fernando L. Dias, Rodrigo S.C. Guindalini, Ulisses R. Nicolau, Andrey Soares, Paulo A.R. Mora Source Type: research